Barclays Maintains Overweight on Natera, Raises Price Target to $475
10/7/2026
Impact: 80
Healthcare
Barclays analyst Luke Sergott has maintained an Overweight rating on Natera (NASDAQ: NTRA) and raised the price target from $340 to $475. This adjustment reflects a positive outlook on the company's performance.
AI summary, not financial advice
Share: